Stock RAPT RAPT THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-31 EDT 		5-day change 1st Jan Change
4.01 USD -0.99% Intraday chart for RAPT Therapeutics, Inc. -4.07% -83.86%
05-14 Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform MT
05-10 Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform
MT
Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy
MT
Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4
MT
US Equity Markets Close Higher Thursday as Jobless Claims Climb
MT
Sector Update: Health Care Stocks Higher Late Afternoon
MT
Sector Update: Health Care
MT
RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials
MT
RAPT Therapeutics Shares Hit 52-Week Low After Trials Closed
DJ
RAPT Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
RAPT Therapeutics Reports First Quarter 2024 Financial Results
GL
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
GL
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
AQ
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
CI
JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating
MT
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) dropped from S&P Biotechnology Select Industry Index
CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
PR
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
GL
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RAPT Stock
  4. News RAPT Therapeutics, Inc.